At Orphai Therapeutics, we are focused on identifying and developing treatments for conditions with unmet medical need. Our current drug candidate targets several disorders including pulmonary hypertension associated with interstitial lung disease (PH-ILD), bronchiolitis obliterans post lung transplant (BOS), and sarcoidosis associated pulmonary hypertension (SAPH).
